Drugs / Yogliptin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05318326 | Jan 2022 → Dec 2024 | type 2 diabetes mellitus | Chengdu Easton Biopharmaceuticals Co,Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yogliptin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05318326 ↗ |
| Route | Oral | “Yogliptin 400mg (4 tablet) , Q1W, oral” NCT05318326 ↗ |